Zobrazeno 1 - 10
of 3 283
pro vyhledávání: ''
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 37:556-564
Purpose: To investigate the influence of benzalkonium chloride (BAK) on ocular surface disease (OSD) in glaucoma patients receiving ocular-hypotensive agent. Methods: Patients were randomized to re...
Autor:
Ali Unlu, Gulsum Abusoglu, Fatma Humeyra Yerlikaya, Dilek Tezcan, Duygu Eryavuz Onmaz, Sema Yilmaz, Mustafa Onmaz, Sedat Abusoglu
Publikováno v:
Inflammopharmacology
Hydroxychloroquine has attracted attention in the treatment of COVID-19. Many conflicting findings have been reported regarding the efficacy and safety of this drug, which has been used safely in the rheumatological diseases for years. However, these
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Antonio Asti, Roberta Bottino, Valerio Langella, Domenico Pomponi, Gisella Di Palma, Vincenzo Russo, Claudia Sassone, Egidio Imbalzano, Giulio Maresca
Publikováno v:
Expert Review of Clinical Pharmacology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Purpose: We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients. Methods: We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitte
Autor:
Nilanjan Ghosh, Bruno Emond, Qing Huang, Aurélie Côté-Sergent, Marie-Hélène Lafeuille, Patrick Lefebvre
Publikováno v:
Clinical Therapeutics. 43:1285-1299
PURPOSE This study assessed treatment patterns in patients with mantle cell lymphoma (MCL) and compared health care resource utilization (HRU) and costs of ibrutinib with or without rituximab (I ± R) versus chemoimmunotherapy (CIT) in patients with
Autor:
Cathrin Sauer, Hannelore Findeis, James Rucker, Michael Bauer, Allan H. Young, Philipp Ritter, Vera M Ludwig
Publikováno v:
CNS Drugs
Background (Es)ketamine and monoamine oxidase inhibitors (MAOIs), e.g., tranylcypromine, are therapeutic options for treatment-resistant major depression. Simultaneous administration is currently not recommended because of concern about hypertensive
Autor:
Joachim Alexandre, Basile Chrétien, Olivier Dejardin, Charles Dolladille, Sophie Fedrizzi, Gilles Defer, Laure Peyro-Saint-Paul
Publikováno v:
Neurotherapeutics
The risk of cancer associated with persons with multiple sclerosis (pwMS) prescribed with disease modifying therapies (DMTs) is not well established. This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety
Autor:
Dermot F. McGinnity, Diansong Zhou, Shringi Sharma, Buyun Chen, Venkatesh Pilla Reddy, Karthick Vishwanathan, Adrian J. Fretland, Joseph Ware, Yan Xu
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy